At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 70 target
Drug / intervention
ICP-723drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
In Brief
A Phase 2 clinical trial evaluating ICP-723 for Advanced Solid Tumors Harboring NTRK Fusion and Primary Central Nervous System Tumors Harboring NTRK Fusion. Currently recruiting, targeting 70 participants across 1 site.
Detailed Summary
A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous System Tumors
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors Harboring NTRK Fusion, Primary Central Nervous System Tumors Harboring NTRK Fusion
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
2023202420252026202720282029
Enrollment StartDec 2022
First PostedFeb 2023
TodayJul 2026
Primary CompletionDec 2027
Study CompletionDec 2028
First PostedFeb 27, 2023
Enrollment StartDec 27, 2022
Primary CompletionDec 25, 2027
Study CompletionDec 25, 2028
TodayJul 1, 2026
Enrollment to primary: 5.0 yearsPosted 3.3 years agoPrimary completion in 1.5 years
Interventions
ICP-723drug
ICP-723 tablet administered orally，once a day，for every 28 days as one cycle